Expert Rev Endocrinol Metab. 2010;5(4):507-516. The 'Summary of Product Characteristics' for BIAsp 30 has recently been changed to reflect data from the clinical trial program. These data showed that ...
Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...
HAMBURG, Germany -- Faster-acting insulin aspart was safe for pregnant women with type 1 or 2 diabetes and resulted in fewer events of hypoglycemia, the randomized CopenFast trial found. The mean ...
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and children with diabetes, the agency announced Friday. Like its reference ...
COPENHAGEN, Jan 8 (Reuters) - Denmark's Novo Nordisk (NOVOb.CO), opens new tab said on Monday its COMBINE 3 phase 3a drug trial had shown that a weekly injection of IcoSema was superior in controlling ...
COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in ...
Biocon Biologics and Civica announced a strategic collaboration agreement to expand access and affordability of Insulin Aspart in the United States. Under the terms of the agreement, Biocon Biologics ...
Insulin is an essential medicine that helps the body turn food into energy and regulate blood sugar levels for millions of people with diabetes nationwide. That makes access to insulin vital for ...
Treatment with once-weekly IcoSema demonstrated noninferiority in HbA1c reduction at week 52 compared with insulin glargine and aspart. Treatment with once-weekly IcoSema, a fixed-ratio combination of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback